Short ReportIdentifying gaps in the implementation of naloxone programs for laypersons in the United States
Section snippets
Background
The opioid epidemic in the United States (US) continues to generate significant increases in morbidity and mortality with no sign of decline. In 2014, the drug overdose mortality rate was 14.7 per 100,000 (Rudd, Aleshire, Zibbell, & Gladden, 2016), and the age-adjusted opioid overdose mortality rate rose nearly 200% from 2000 to 2014 (Rudd, Aleshire et al., 2016). Opioid-involved overdose deaths increased another 16% from 2014 to 2015, fueled by an increase in deaths involving heroin and
Study population
Our study population includes all 3142 counties in the 50 United States and District of Columbia in 2014.
Data sources
We combined two different data sources: (a) drug overdose mortality, as captured in the National Vital Statistics System from the National Center for Health Statistics (NCHS) (Rossen, Bastian, Warner, Khan, & Chong, 2017); and (b) existing OEND programs from a database that was developed to determine the location and effective dates of all programs that distribute naloxone to laypersons in
Results
In total, 8% (254) of counties in the US had established OEND programs by the time of the HRC survey in 2014, and counties with the highest overdose mortality rates had very low implementation of OEND programs – 12% of counties with >18–≤24 deaths per 100,000, and 13% of counties with >24 deaths per 100,000 had established OEND programs [Fig. 1]. The counties with the lowest overdose mortality rates were least likely to have OEND programs established – <1% of counties with ≤6 deaths per
Discussion
Given the scope of the opioid epidemic in the United States, we observed strikingly low levels of OEND programs established throughout the country. While counties experiencing the highest rate of drug overdose mortality (>24/100,000) did have the highest percentage of OEND programs in our analysis, these programs were operating in only 13% of these high burden counties. The relatively low volume of OEND coverage throughout the United States highlights a critical implementation gap in the
Conflict of interest statement
We declare that we have no conflicts of interest.
Acknowledgement
This research was conducted with funding from the National Institute of Drug Abuse (R34DA039101).
References (15)
- et al.
Naloxone for heroin, prescription opioid, and illicitly made fentanyl overdoses: Challenges and innovations responding to a dynamic epidemic
The International Journal on Drug Policy
(2017) - et al.
Why are some people who have received overdose education and naloxone reticent to call Emergency Medical Services in the event of overdose?
The International Journal on Drug Policy
(2017) - et al.
Hot spots in mortality from drug poisoning in the United States, 2007–2009
Health and Place
(2014) - et al.
Prescription naloxone: A novel approach to heroin overdose prevention
Annals of Emergency Medicine
(2007) - et al.
Cost-effectiveness of distributing naloxone to heroin users for lay overdose reversal
Annals of Internal Medicine
(2013) - et al.
Nonrandomized intervention study of naloxone coprescription for primary care patients receiving long-term opioid therapy for pain
Annals of Internal Medicine
(2016) Drug Facts: Fentanyl
(2016)